Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia

This study is an open-label, prospective investigation designed to enroll 100 high-risk pregnant subjects with preeclampsia (PE). Participants will be allocated in a 2:2:1 ratio to one of three groups: the Topefilgrastim 0.5mg/biweekly group, the Topefilgrastim 1mg/biweekly group, or the control group, based on investigator judgment and patient preference. The overall study consists of three parts: a screening period, a treatment period, and a follow-up period.

NCT Number	NCT07384936
Lead Sponsor	Fang Wang Collaborators: Xiamen Amoytop Biotech Co., Ltd.
Conditions	Preeclampsia
Enrollment	100 participants
Start Date	2026-01-31
Primary Completion	2027-05 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-03